Members login

Library

Conference documents

VICH 7 Conference (November 13 & 14, 2024 in Amsterdam, Europe)

Group Picture 1 - Group Picture 2 - Group Picture 3

Session 2: Keynote Addresses

Why WOAH is a strong advocate of VICH - Maria Szabo
How is VICH responding to global needs in a new era ?a ? - Matthew Lucia
VICH achievements - Hervé Marion

Session 3: VICH moving forwards

Restructuring (and future vision) - Shoko Iwamoto
VICH Workplan - Margaret Churchill
The view of a VICH Forum member - Yuriy Kosenko

Session 4: How VICH guidelines are developed, implemented and used

How VICH guidelines are developed, implemented and used - Brigitte Boenisch
How VICH guidelines implement the 3Rs in safety studies - Esther Werner
Challenges and perspectives in adopting VICH guidelines in VICH Forum countries/regions and how to overcome them - Adelaide Ayoyi Ogutu

Session 5: Scientific issues

Scientific topic 1: Safety of monoclonal antibodies - Catrina Stirling
Scientific topic 2: Pharmacovigilance and signal management - Kathrin Schirmann
Scientific topic 3: Bioequivalence and dissolution testing - Marilyn Martinez

Session 6: New or revised VICH GLs

GL topic 1: Anthelmintics - Aimee Phillippi-Taylor
GL topic 2: Good manufacturing practice for active pharmaceutical ingredients - Mai Huynh
GL topic 3: Pharmaceutical development - Mai Huynh

Session 7: Opportunities from international guidelines and regional collaboration

International collaboration - Marilena Bassi
GMP Inspections Reliance Programmes and Mutual Recognition Agreements - Gregory Verdier and Piotr Krauze
Regional collaboration and mutual reliance - Innocent Ravengai

Session 8: Technical challenges

New science in veterinary biologics - Kota Sato
New science and reduction in the use of experimental animals - Sarah Adler-Flindt
Real world evidence and big data - Ricardo Carapeto

Session 9: The future

The expectations from a VICH Forum member - Barbara Borges Cordeiro
Inspired by VICH: International Forum on in vitro diagnostics - Jennifer-Christelle Essolomwa
Supported by VICH: Regulatory convergence - Carel du Marchie Sarvaas
The Vision for the future - Ivo Claassen

VICH EWGs Posters exhibited during the conference:

Pictures of the Gala Dinner held on 13 November 2024 at the Groote Museum (Royal Hall):

Royal Hall: 1 - 2
Reception: 1 - 2 - 3 - 4
General Views: 1 - 2 - Royal Hall Row 1 - Royal Hall Row 2 - Royal Hall Row 3 - Royal Hall Row 4
R. Feller's Welcome Speech (Secretary Genaral of AnimalhealthEurope): 1 - 2 - 3 - 4
Menu: Starter - Main Course - Dessert
"Beste Bands" - Flash Mob: Flash Mob Group - 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - Video (MP4)
"Paloina" - Dutch Dancers and Singers: 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 - 11 - 12 - 13 - 14 - 15 - 16 - 17 - 18 - 19 - 20 - Video 1 (MP4) - Video 2 (MP4)

--------------------------------------------------------------------------------

VICH 6 Conference (February 27 & 28, 2019 in Cape Town, South Africa)

Session 1: Official Opening

What is VICH, History and Objectives - Dr. H. Marion
What does the OIE see as the benefits of the VICH to OIE members - Dr. G. Brucker

Session 2: Keynote Addresses

What does an Outreach Forum member see as the benefits of VICH - Dr. S. Yunus
The contribution of VICH to the Global One Health Approach - Focus on antimicrobial resistance - Dr. J-P. Orand
Training benefits gained by Outreach Forum members - Dr. T. Huang-Fu

Session 3: Implementing VICH Guidelines

BY VICH Observer - Dr. M.J. Ireland
By VICH Member - Ms. B. Robinson
Possible regulatory obstacles and perspectives in adopting VICH GLs in VOF countries/regions and how to overcome them - Dr. Y. Kosenko

Session 4: Voice of Industries

Stimulating innovation - Dr. E. De Ridder
Regulatory convergence - Dr. A. Böttner
Animal Health Product availability and accessability - Dr. G. Agède

Session 5: Existing VICH GLs - Hot Topics

Academia's view of the benefits of VICH - Prof. V. Naidoo
VICH and the 3Rs - Dr. N. Jarrett
Waiver of Target Animal Batch Safety Test - Dr. N. Nwankpa

Session 6: New VICH GLs

Climatic Zone III / IV Stability Guideline - Prof. H. Leng
Combination Products GL - Ms. B. Robinson
New MRK GLs - Aquatic species and honey - Dr. S. Scheid

Session 7: African Regional Activities

A public, private partnership to expedite product registrations - Ms. M. Churchill
The Zazibona work sharing experience in the SADC region - Dr. Z. Makoni
Pharmacovigilance - the East Africal electronic system of reporting - Dr. N. Aineplan

Session 8: Global Perspectives

Regulatory perspective on global trends in veterinary biologics - Dr. B. Rippke
Why global regulatory convergence is important - Dr. S. Thevasagayam

Session 9: Expectations for VICH

VOF expectations - Dr. A. Teko-Agbo
VICH and veterinary medicines availability - Improvement of global animal & human health - Dr. J. Lwoyero

Session 10: Vision for the future

The vision for the future - Dr. M. Lucia

VICH 5 Conference (October 28 & 29, 2015 in Tokyo, Japan)

Session 1: Official Opening

What is VICH, History and Objectives - Dr. Hervé Marion - VICH Secretariat
The benefits of VICH to the VICH member countries & regions - Dr. Donald Prater - U.S. FDA

Session 2: Keynote Addresses

The contribution of VICH to the global One Health approach - Dr. Jean-Pierre Orand - OIE
The benefits of VICH to emerging countries - Dr. Sasi Jaroenpoj - Thailand/ASEAN
The needs and expectations of a global industry - Mr. Carel du Marchie Sarvaas - HealthforAnimals
VICH/OIE training strategy - Dr. Steven Vaughn - U.S. FDA

Session 3: How to use VICH guidelines

Session 4: Voice of Industries

Trends in research and development of new veterinary drug substances and products - Dr. Mark Micallef - Zenoaq, Japan
Benchmarking the Livestock Business Environment - Mrs. Edna Kallon - World Bank, USA

Session 5: Contribution to animal welfare in tests for VMPs

Statement of principle for VICH the "3R" approach & Alternatives to Animal Testing - Dr. Nicholas Jarrett - EU/VICH EU coordinator
Waiver of Target Animal Batch Safety Test - Dr. Marlies Halder - EU/Topic leader for TABST in the BQM EWG

Session 6: VICH NOW

The VICH pharmacovigilance guidelines - Dr. Margarita Brown - FDA
Bioequivalence - Dr. Marilyn Martinez - FDA

Session 7: Topics of particular interest for Observer Countries and VOF members

Development of a VICH guideline on stability studies to address climatic zones III and IV - Dr. Alice Sigobodhla - Department of Health, South Africa
New VICH guideline on residue studies in aquatic species - Dr. Pamela Boner - Zoetis/Topic leader for aquatic species in the MRK EWG
New VICH guideline on the efficacy studies for combination products - Dr. Ken Noda - JMAFF

Session 8: Ongoing Activities: Global Perspectives

Outcome of the HealthforAnimals 2015 Global Animal Health Conference - Dr. Bettye Walters - Center for Veterinary Medicine, U.S. FDA
Regulatory perspective on trends in veterinary biologics - Dr. Byron Rippke - Center for Veterinary Biologics at USDA, APHIS, VS, CVB
Why regulatory convergence is important - Mr. Samuel J. Thevasagayam - Bill & Melinda Gates Foundation

Session 9: Finale

The expectations from VICH Outreach Forum members - Dr. Carlos Francia - CAPROVE
VICH and veterinary medicines availability - improvement of global animal & human health - Dr. Jean-Pierre Orand - OIE
The Vision for the future - Dr. Yuko Endo - NVAL, JMAFF

VICH 4 Conference (June 24 & 25, 2010 in Paris)

VICH EWGs Posters (in pdf) - The posters exhibited during the conference are in the attachments
Presentations
Pictures of the conference

Attachments